Barth: Why BBR uses generalists instead of asset-class investment specialists
Brett Barth · Brett Barth – Asset Allocation for Families (Capital Allocators, EP.03) · Apr 20, 2017 · at 43:47
Brett Barth, Co-Founder of BBR Partners, discusses why BBR employs generalist senior research professionals rather than dedicated asset-class specialists.
0:00 / 0:15exact quote · 15.4s
720p mp4 · rendered on demand · StarZero watermark
“First, from a structural perspective, all of the senior people are generalists, and so if you're a hammer, everything looks like a nail. If you're the private equity specialist, Every investment problem has a solution that looks like a private equity fund.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Brett Barth
Barth: Retail flows will swamp Ivy League endowment private market capital
“And notwithstanding the endowment headlines, we think a much bigger fund flow that's going to swamp that is the democratization. It's the retail flows. Almost everything we're doing in illiquids is either to get paid to access that, seed things that can take a…”
Barth: Multi-manager hedge funds will take the biggest hit if endowments face taxes
“The places where you're going to see bigger hits are on the multi-manager pod hedge funds, which are incredibly tax inefficient, but have been a good source of risk-adjusted returns for some of the larger tax-exempt allocators. That's where I think the bigger …”
Barth: International betas are the most attractive in 15 to 20 years
“I think the betas are more interesting than they've been in 15 or 20 years because of not just the entry point, but because of the deglobalization, and you've got a declining correlation of those markets, and the only free lunch we get as allocators is diversi…”
Barth: Dislocated biotech sector presents massive multi-asset investment opportunities
“One of the places where we see public, private, and credit incredibly dislocated, unloved, and where we think there's huge opportunity is biotech. It has been such a bubble through the pandemic where biotech and vaccines were going to solve everything, and now…”